InflaRx intends to engage with EMA regarding both vilobelimab and izicopan to evaluate the regulatory path to approval in ANCA-associated ...

Managing complement 3 glomerulopathy involves several treatment options aimed at slowing disease progression and protecting kidney function. These may include blood pressure control, steroids, ...

There are two types of complement 3 glomerulopathy: dense deposit disease (DDD) and C3 glomerulonephritis (C3GN). DDD often begins earlier in life and may progress more quickly. Both are linked to an ...

Deep in our cells, a wide range of processes are occurring constantly. These cellular processes rely on enzymes to act as catalysts and set off a series of molecular interactions. There are still many ...

A rare but severe stem cell transplant complication that often becomes fatal now has its first FDA-approved treatment, a therapy developed by biotechnology company Omeros. The Christmas Eve regulatory ...

Please provide your email address to receive an email when new articles are posted on . In the complex, multifactorial pathophysiology of glaucoma, as in most neurodegenerative diseases, inflammatory ...

The EXENT System integrates immunoassay, mass spectrometry, and data review software to improve multiple myeloma diagnosis accuracy and workflow efficiency. FDA 510(k) clearance confirms the EXENT ...

Dysregulated complement pathways are linked to progression from iAMD to advanced AMD, including NVAMD and GA. Higher systemic levels of C4, C4b, and a reduction in C3 are associated with increased ...

A team of scientists has uncovered how an ancient immune system, the complement system, decides when to launch an attack—revealing a hidden mathematical tipping point based on the spatial density of ...

A collaborative team from the School of Engineering and Applied Science and the Perelman School of Medicine have unraveled the mathematics of a 500-million-year-old protein network that acts like the ...

The Complement System (CS) comprises three catalytic pathways that can be activated by specific immune triggers. However, within the tumor microenvironment (TME), CS intracellular components, recently ...